Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition

Treatment of advanced stage anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) with ALK tyrosine kinase inhibitors (TKIs) has been shown to be superior to standard platinum-based chemotherapy. However, secondary progress of disease frequently occurs under ALK inhibitor trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemper, Marcel, Evers, Georg, Schulze, Arik Bernard, Sperveslage, Jan, Schülke, Christoph, Lenz, Georg, Herold, Thomas, Hartmann, Wolfgang, Schildhaus, Hans-Ulrich, Bleckmann, Annalen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448518/
https://www.ncbi.nlm.nih.gov/pubmed/34548910
http://dx.doi.org/10.18632/oncotarget.28062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448518/
https://www.ncbi.nlm.nih.gov/pubmed/34548910
http://dx.doi.org/10.18632/oncotarget.28062

Ejemplares similares